The Use of Dornase Alfa in the Management of COVID-19-Associated Adult Respiratory Distress Syndrome
Objective. Currently, management of acute respiratory distress syndrome (ARDS) in COVID-19 infection with invasive mechanical ventilation results in poor prognosis and high mortality rates. Interventions to reduce ventilatory requirements or preclude their needs should be evaluated in order to impro...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2021-01-01
|
| Series: | Critical Care Research and Practice |
| Online Access: | http://dx.doi.org/10.1155/2021/8881115 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850164571427307520 |
|---|---|
| author | Andrew Toma Christina Darwish Michele Taylor Justin Harlacher Ribal Darwish |
| author_facet | Andrew Toma Christina Darwish Michele Taylor Justin Harlacher Ribal Darwish |
| author_sort | Andrew Toma |
| collection | DOAJ |
| description | Objective. Currently, management of acute respiratory distress syndrome (ARDS) in COVID-19 infection with invasive mechanical ventilation results in poor prognosis and high mortality rates. Interventions to reduce ventilatory requirements or preclude their needs should be evaluated in order to improve survival rates in critically ill patients. Formation of neutrophil extracellular traps (NETs) during the innate immune response could be a contributing factor to the pulmonary pathology. This study suggests the use of dornase alfa, a recombinant DNAse I that lyses NETs, to reduce ventilatory requirements and improve oxygenation status, as well as outcomes in critically ill patients with ARDS subsequent to confirmed or highly suspected COVID-19 infection. Design. A single-institution cohort study. Setting. Intensive care unit in a tertiary medical center. Patients. Adult patients with acute respiratory distress syndrome (ARDS) admitted to the ICU with confirmed COVID-19 infection. Intervention. Treatment with aerosolized dornase alfa. Measurements and Main Results. Of 39 patients evaluated, most patients had improvement in oxygenation measured by increase in the PaO2/FiO2 ratio, reduction in ventilatory support or other supportive oxygen requirements, and partial resolution of bilateral opacities visible on CXR, as well as improved outcome. Conclusions. Administration of inhalational dornase alfa via a filtered nebulizer medication system or through an adapter in a ventilator circuit should be considered in all COVID-19-positive patients with ARDS as early in the disease course as possible. |
| format | Article |
| id | doaj-art-ea0a9ada8d1647e898263a6162e40450 |
| institution | OA Journals |
| issn | 2090-1305 2090-1313 |
| language | English |
| publishDate | 2021-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Critical Care Research and Practice |
| spelling | doaj-art-ea0a9ada8d1647e898263a6162e404502025-08-20T02:21:57ZengWileyCritical Care Research and Practice2090-13052090-13132021-01-01202110.1155/2021/88811158881115The Use of Dornase Alfa in the Management of COVID-19-Associated Adult Respiratory Distress SyndromeAndrew Toma0Christina Darwish1Michele Taylor2Justin Harlacher3Ribal Darwish4Palm Beach Gardens Medical Center, Palm Beach Gardens, FL, USAGeorge Washington University, School of Medicine and Health Sciences, Washington, DC, USAPalm Beach Gardens Medical Center, Palm Beach Gardens, FL, USAPalm Beach Gardens Medical Center, Palm Beach Gardens, FL, USAPalm Beach Gardens Medical Center, Palm Beach Gardens, FL, USAObjective. Currently, management of acute respiratory distress syndrome (ARDS) in COVID-19 infection with invasive mechanical ventilation results in poor prognosis and high mortality rates. Interventions to reduce ventilatory requirements or preclude their needs should be evaluated in order to improve survival rates in critically ill patients. Formation of neutrophil extracellular traps (NETs) during the innate immune response could be a contributing factor to the pulmonary pathology. This study suggests the use of dornase alfa, a recombinant DNAse I that lyses NETs, to reduce ventilatory requirements and improve oxygenation status, as well as outcomes in critically ill patients with ARDS subsequent to confirmed or highly suspected COVID-19 infection. Design. A single-institution cohort study. Setting. Intensive care unit in a tertiary medical center. Patients. Adult patients with acute respiratory distress syndrome (ARDS) admitted to the ICU with confirmed COVID-19 infection. Intervention. Treatment with aerosolized dornase alfa. Measurements and Main Results. Of 39 patients evaluated, most patients had improvement in oxygenation measured by increase in the PaO2/FiO2 ratio, reduction in ventilatory support or other supportive oxygen requirements, and partial resolution of bilateral opacities visible on CXR, as well as improved outcome. Conclusions. Administration of inhalational dornase alfa via a filtered nebulizer medication system or through an adapter in a ventilator circuit should be considered in all COVID-19-positive patients with ARDS as early in the disease course as possible.http://dx.doi.org/10.1155/2021/8881115 |
| spellingShingle | Andrew Toma Christina Darwish Michele Taylor Justin Harlacher Ribal Darwish The Use of Dornase Alfa in the Management of COVID-19-Associated Adult Respiratory Distress Syndrome Critical Care Research and Practice |
| title | The Use of Dornase Alfa in the Management of COVID-19-Associated Adult Respiratory Distress Syndrome |
| title_full | The Use of Dornase Alfa in the Management of COVID-19-Associated Adult Respiratory Distress Syndrome |
| title_fullStr | The Use of Dornase Alfa in the Management of COVID-19-Associated Adult Respiratory Distress Syndrome |
| title_full_unstemmed | The Use of Dornase Alfa in the Management of COVID-19-Associated Adult Respiratory Distress Syndrome |
| title_short | The Use of Dornase Alfa in the Management of COVID-19-Associated Adult Respiratory Distress Syndrome |
| title_sort | use of dornase alfa in the management of covid 19 associated adult respiratory distress syndrome |
| url | http://dx.doi.org/10.1155/2021/8881115 |
| work_keys_str_mv | AT andrewtoma theuseofdornasealfainthemanagementofcovid19associatedadultrespiratorydistresssyndrome AT christinadarwish theuseofdornasealfainthemanagementofcovid19associatedadultrespiratorydistresssyndrome AT micheletaylor theuseofdornasealfainthemanagementofcovid19associatedadultrespiratorydistresssyndrome AT justinharlacher theuseofdornasealfainthemanagementofcovid19associatedadultrespiratorydistresssyndrome AT ribaldarwish theuseofdornasealfainthemanagementofcovid19associatedadultrespiratorydistresssyndrome AT andrewtoma useofdornasealfainthemanagementofcovid19associatedadultrespiratorydistresssyndrome AT christinadarwish useofdornasealfainthemanagementofcovid19associatedadultrespiratorydistresssyndrome AT micheletaylor useofdornasealfainthemanagementofcovid19associatedadultrespiratorydistresssyndrome AT justinharlacher useofdornasealfainthemanagementofcovid19associatedadultrespiratorydistresssyndrome AT ribaldarwish useofdornasealfainthemanagementofcovid19associatedadultrespiratorydistresssyndrome |